title: Nitric oxide attenuates matrix metalloproteinase-9 production by endothelial cells independent of cGMP- or NFκB-mediated mechanisms.
abstract: Cardiovascular diseases involve critical mechanisms including impaired nitric oxide (NO) levels and abnormal matrix metalloproteinase (MMP) activity. While NO downregulates MMP expression in some cell types, no previous study has examined whether NO downregulates MMP levels in endothelial cells. We hypothesized that NO donors could attenuate MMP-9 production by human umbilical vein endothelial cells (HUVECs) as a result of less NFκB activation or cyclic GMP (cGMP)-mediated mechanisms. We studied the effects of DetaNONOate (10-400 μM) or SNAP (50-400 μM) on phorbol 12-myristate 13-acetate (PMA; 10 nM)-induced increases in MMP-9 activity (by gel zymography) or concentrations (by ELISA) as well as on a tissue inhibitor of MMPs' (TIMP)-1 concentrations (by ELISA) in the conditioned medium of HUVECs incubated for 24 h with these drugs. We also examined whether the irreversible inhibitor of soluble guanylyl cyclase ODQ modified the effects of SNAP or whether 8-bromo-cGMP (a cell-permeable analog of cGMP) influenced PMA-induced effects on MMP-9 expression. Total and phospho-NFκB p65 concentrations were measured in HUVEC lysates to assess NFκB activation. Both NO donors attenuated PMA-induced increases in MMP-9 activity and concentrations without significantly affecting TIMP-1 concentrations. This effect was not modified by ODQ, and 8-bromo-cGMP did not affect MMP-9 concentrations. While PMA increased phospho-NFκB p65 concentrations, SNAP had no influence on this effect. In conclusion, this study shows that NO donors may attenuate imbalanced MMP expression and activity in endothelial cells independent of cGMP- or NFκB-mediated mechanisms. Our results may offer an important pharmacological strategy to approach cardiovascular diseases.
authors: Department of Pharmacology, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil.
authors: Cesar A
authors: CA
authors: Meschiari
authors: Tatiane
authors: T
authors: Izidoro-Toledo
authors: Raquel F
authors: RF
authors: Gerlach
authors: Jose E
authors: JE
authors: Tanus-Santos
mesh_terms: D002478:Cells, Cultured; D017077:Culture Media, Conditioned; D006152:Cyclic GMP / Q000502:physiology*; D004794:Enzyme Repression / Q000187:drug effects; D015870:Gene Expression; D061307:Human Umbilical Vein Endothelial Cells / Q000201:enzymology*; D006801:Humans; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism*; D009569:Nitric Oxide / Q000494:pharmacology / Q000502:physiology*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D009570:Nitriles / Q000494:pharmacology; D009603:Nitroso Compounds / Q000494:pharmacology; D010766:Phosphorylation; D011499:Protein Processing, Post-Translational; D013450:Sulfones / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000235:genetics / Q000378:metabolism; D051996:Transcription Factor RelA / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014158:Transcription, Genetic
chemical_list: C434003:3-(4-methylphenylsulfonyl)-2-propenenitrile; D017077:Culture Media, Conditioned; D020030:Nitric Oxide Donors; D009570:Nitriles; D009603:Nitroso Compounds; C498143:RELA protein, human; D013450:Sulfones; C560822:TIMP1 protein, human; D019715:Tissue Inhibitor of Metalloproteinase-1; D051996:Transcription Factor RelA; C094210:2,2'-(hydroxynitrosohydrazono)bis-ethanamine; D009569:Nitric Oxide; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9; D006152:Cyclic GMP; D013755:Tetradecanoylphorbol Acetate